Ziritaxestat Failure Could Spell End For Gilead/Galapagos Pact
IPF And Systemic Sclerosis Trials Abandoned
The Galapagos and Gilead partnership has had a tough few months and the failure of ziritaxestat, plus the decision not to develop filgotinib Stateside for rheumatoid arthritis, is calling into question the merits of the whole collaboration for the US biotech.
You may also be interested in...
But the partners will have to avoid the pitfalls that have bedevilled several other expensive licensing deals.
Roche’s decision to discontinue a Phase III program in idiopathic pulmonary fibrosis was the latest of several recent late-stage clinical failures, emblematic of the difficulty in finding new approaches to treat the disease.
Analysts are scratching their heads over what direction the Belgian biotech will take in the coming months and years, with all eyes on an R&D day in October.